KYLEENA 19.5 mg, drug release system intrauterine
Active ingredients: Levonorgestrel
Commercialized according to BDPMDispensing in France: Prescription only
Drug release system1 plaquette(s) thermoformée(s) polytéréphtalate (PET) de 1 dispositif(s)intra-utérine
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- KYLEENA 19,5 mg, système de diffusion intra-utérin
- Pharmaceutical form
- système de diffusion
- Route of administration
- intra-utérine
- Presentation description
- 1 plaquette(s) thermoformée(s) polytéréphtalate (PET) de 1 dispositif(s)
- Marketing authorisation holder
- BAYER HEALTHCARE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Mar 2018
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63463104CIP73009475CIP133400930094754Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉVONORGESTRELsystème de diffusion | 19,50 mg · un système | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.